Romiplostim Biosimilar Candidate

Due to the complex nature of the product, Paras Biopharmaceuticals has been intensively working on this complex drug (Nplate™) for over 6 years and has progressively achieved success. The company plans to mature good value within its Romiplostim asset (Biosimilar) and would like to highlight the following points / highlights to gauge your level of interest. Nplate™ (originator – Amgen Inc) indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) – characterized by low platelet count in the blood. Won “Best New Drug” in 2009 – Now coming off-patent in 2026 & 2028. Nplate™ was the first platelet producer approved by the FDA and EMA. Works by raising and sustaining platelet counts, representing a unique approach for the long-term treatment of ITP. Paras Biopharmaceuticals have worked very extensively on Romiplostim and have development, substantial data (unique program) For European approval and registration of Romiplostim, Paras Biopharmaceuticals expects that we need to carry out “direct to patient” clinical studies. For further development and registration / approval, very limited further expenses are to made and hence the partnership. Furthermore, Paras Biopharmaceuticals seems to be the only company other than the innovator on such program. Paras Biopharmaceuticals looks to mature maximum value to the pool / joint sharing for further growth / return / rewards from the program. If you have an interest in the product and would like to know more, we would welcome the opportunity to set up a onsite meeting.